Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer

2.1 Apalutamide (Erleada, Janssen) is indicated 'in adult men for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease'.

2.2 The dosage schedule is available in the summary of product characteristics.

2.3 The price for apalutamide is £2,735 per pack of 112 tablets, each containing 60 mg of the active ingredient (excluding VAT; BNF online, March 2021). The company has a commercial arrangement (simple discount patient access scheme). This makes apalutamide available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.